What Omgeneum does

OMGENEUM Inc. (operating as Omgeneum) is a privately held regenerative bioengineering company incorporated in San Juan, Puerto Rico, with a Japan Branch Preparation Office in Hamamatsu City. The company develops a multifaceted platform targeting neurodegenerative diseases and severe neurological conditions — including Alzheimer's, Parkinson's, stroke, traumatic brain injury, disorders of consciousness, and psychiatric disorders — that it characterizes as having no effective treatment or cure under conventional medicine.

The core technology stack rests on three proprietary components: MiRi-X1 (modulated autologous or allogeneic stem cells driven into neurogenesis-patterned expression programs), iRis (integrated Regenerative inducing Systems — wearable neuro/biomodulation devices using bioelectric, magnetic, mechanical/acoustic, and photobiomodulation to induce endogenous gene and protein expression), and ARMADYNE Insights (an AI-powered digital therapeutics ecosystem positioned to integrate patient outcome data and accelerate regenerative modality discovery). Treatments are delivered through the Omgeneum Brain Center, a specialized medical facility offering integrated, multidisciplinary care combining stem cell transplantation with supportive neurorehabilitation and iRis-based neuromodulation.

Commercially, the company operates a direct-to-patient professional services model without publicly disclosed pricing, payer relationships, or revenue figures. The 11-50 employee organization is privately held with no disclosed institutional investors, funding rounds, or regulatory milestones (e.g., FDA approval, IND clearance). A Japan branch office signals intent to internationalize the clinical model, while affiliated entities (ARMADYNE Corp., ÉlpisÉremo) suggest a multi-entity IP and operations structure rather than a single corporate vehicle.

Name

Omgeneum

Legal name

OMGENEUM Inc.

Website

https://omgeneum.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Omgeneum is a privately held regenerative bioengineering company operating a Brain Center in Puerto Rico that delivers AI-augmented stem cell and neuro/biomodulation therapies for neurodegenerative diseases including Alzheimer's, Parkinson's, stroke, and traumatic brain injury.

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071)

akta.pro primary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

Keywords

• Regenerative biotechnology
• Stem cell therapy
• Neurodegenerative treatments
• AI digital therapeutics
• Brain modulation devices

Headquarters

HQ city

San Juan

HQ country

Puerto Rico

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Stem Cell Treatment Services: Medical treatment services utilizing proprietary regenerative medicine including stem cell therapy for various neurological conditions. Treatment involves multiple steps including examination, stem cell transplantation, and hospitalization. Services provided through Omogeneum Brain Center.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

OMGENEUM develops and delivers regenerative biotechnology treatments combining modulated stem cells (MiRi-X1), neuro/biomodulation devices (iRis), and an AI-powered digital therapeutics ecosystem (ARMADYNE Insights) to treat neurodegenerative diseases such as Alzheimer's, Parkinson's, stroke, traumatic brain injury, and disorders of consciousness. Treatments are administered through the specialized Omogeneum Brain Center with dedicated multidisciplinary medical teams following a structured patient journey of examination, stem cell transplantation, hospitalization, and discharge. The company is pioneering what it terms "Resurrection Modalities" – precision curative treatments targeting conditions with no existing effective cure in conventional medicine.

Product overview

OMGENEUM is a regenerative bioengineering technology company developing a multifaceted "precision curative modalities" platform. The core technology portfolio includes MiRi-X1 (modulated stem cells for neurogenesis), iRis (integrated Regenerative inducing Systems - a wearable neuro/biomodulation device), and ARMADYNE Insights (AI-powered digital therapeutics ecosystem). The company operates the Omgeneum Brain Center offering stem cell treatments for neurodegenerative diseases and traumatic brain conditions including stroke, Alzheimer's, Parkinson's, acquired brain injury, and disorders of consciousness. Treatment services utilize stem cells from multiple sources including bone marrow, Wharton's jelly, cord blood, and donor cells, often combined with iRis neuro-niche modulation helmets powered by the AI platform.

Differentiator

Problem solved

Functional benefit

Brands

• ARMADYNE Insights: AI-Powered digital therapeutics ecosystem that optimizes therapeutic potential of regenerative stem cell treatments and augments delivery of next-generation regenerative technology.
• MiRi-X1
• iRis

Products and services

• Stem Cell Treatment for Stroke
• Stem Cell Therapy for Alzheimer's Disease
• Stem Cell Therapy for Parkinson Disease
• Stem Cell Therapy for Acquired Brain Injury
• Stem Cell Therapy for Disorders of Consciousness
• Omogeneum Brain Center
• ARMADYNE Insights
• MiRi-X1 Modulated Stem Cells
• iRis (Integrated Regenerative inducing Systems)
• Resurrection Modalities

Segments6 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• BrainStorm Cell Therapeutics: Clinical-stage cell therapy developer focused on autologous MSC-based therapies (NurOwn) for neurodegenerative diseases including ALS, MS, and Alzheimer's. Highly comparable to Omgeneum in applying stem cell technology to neurological indications with limited treatment options.
• Mesoblast: Commercial-stage cell therapy company marketing remestemcel-L (allogeneic MSC product) for inflammatory and neurological conditions including pediatric SR-aGvHD and chronic low back pain. Comparable as a vertically integrated stem cell developer with both product development and clinical delivery.
• Pluristem Therapeutics: Developer of PLX ( Placenta-derived, expanded allogeneic adherent stromal cell) cell therapy candidates for peripheral artery disease, muscle injury, and various ischemic/inflammatory indications. Comparable business model combining proprietary cell platform with multi-indication clinical pipeline.
• Stem Cell Institute (Medistem Panama): Panama-based regenerative medicine clinic providing autologous and allogeneic stem cell therapies for autism, multiple sclerosis, Parkinson's, osteoarthritis, and other conditions on a fee-for-service medical-tourism basis. Closely mirrors Omgeneum Brain Center's clinic-led, treatment-services revenue model for neurodegenerative diseases.
• BlueRock Therapeutics (Bayer): Engineered cell therapy company developing iPSC-derived dopaminergic neuron therapies for Parkinson's disease and other neurology indications. Direct competitor in regenerative medicine for neurodegeneration with proprietary cell-engineering platform analogous to Omgeneum's MiRi-X1 modulated stem cells.
• Stemedica Cell Technologies: Clinical-stage stem cell company developing allogeneic mesenchymal and neural stem cell therapies for ischemic stroke, heart failure, and neurodegenerative conditions. Closely comparable to Omgeneum in using stem cell therapies for stroke and CNS indications.

Emerging players

• Vielight: Developer of photobiomodulation (PBM) devices (intranasal and helmet-based) targeting cognitive performance, Alzheimer's, Parkinson's, and traumatic brain injury. Comparable to Omgeneum's iRis wearable neuro/biomodulation device platform in applying light-based and bioelectric modulation to neurological conditions.
• Aspen Neuroscience: Clinical-stage developer of patient-derived (autologous) iPSC-derived dopaminergic neuron cell replacement therapy for Parkinson's disease. Closely comparable to Omgeneum's MiRi-X1 autologous modulated stem cell approach for Parkinson's treatment.
• GH Research: Clinical-stage biotechnology company developing innovative treatments for psychiatric and neurological disorders (depression, PTSD). Comparable to Omgeneum's neuromodulation/AI approach in targeting psychiatric disorders such as depression, anxiety, and PTSD with novel non-pharmacological modalities.

Broad incumbents

• Biogen: Large neurology-focused biopharmaceutical company with commercialized Alzheimer's treatments (Leqembi, Aduhelm) and Parkinson's, SMA, and MS franchises. As a broad incumbent in neurodegeneration therapeutics, Biogen represents the established payer pathway and trial infrastructure Omgeneum must compete with for clinical credibility.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/omgeneum

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Omgeneum